|
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy. Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy. conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy. Clinical research trials and Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy. healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy.. Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy. Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy. clinical trial. Human subjects often obtain the finest healthcare possible for their Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy. condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy.  Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy.
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy.
For Condition: HIV Infections
Status: Completed
Sponsor(s): Hoffmann-La Roche ,
Synopsis: To provide zalcitabine ( ddC ) for patients with AIDS or Advanced ARC in whom zidovudine ( AZT ) is contraindicated, or who have failed treatment with or are intolerant to AZT and to demonstrate that ddC monotherapy is safe, and tolerable in this patient population.
Details:
Eligibility:
Study Type: Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 12 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Aerosolized Pentamidine or Trimethoprim/sulfamethoxazole prophylaxis against Pneumocystis carinii pneumonia is recommended. - Dapsone is permitted but discouraged. - Drugs that could cause other serious toxicity when coadministered with study medication is allowed for treatment of an acute intercurrent illness or opportunistic infection at the investigator's discretion. - Any medication that has the potential to cause peripheral neuropathy should be avoided; patients should consult their physicians for specific drugs. - Isoniazid is permitted if there is no evidence of peripheral neuropathy at entry and the patient is taking pyridoxine = or > 50 mg/day. - Metronidazole is permitted only with a study drug interruption. - Patients on amphotericin, pyrimethamine, sulfadiazine, trimethoprim/sulfamethoxazole, ganciclovir, intravenous pentamidine, intravenous acyclovir = or > 1000 mg/day orally or other bone marrow or renal toxic drugs may not tolerate concomitant ddC. If these drugs are given concomitantly with ddC, patients should have frequent (weekly) laboratory assessments, as appropriate. - Drugs that are nephrotoxic or have the potential to cause peripheral neuropathy might be expected to cause increased toxicity when co-administered with ddC. - The following experimental medications are allowed if, in the judgement of the investigator, no serious additive toxicities are anticipated and the experimental drug is necessary for optimal patient management: - Ampligen, azithromycin, BW 566C80, bovine colostrum, clarithromycin, diclazuril, foscarnet, oral ganciclovir, GM-CSF, G-CSF, hypericin, IL-2, interferon-beta, interferon-gamma, itraconazole, liposomal amphotericin, liposomal gentamicin, nimodipine, PEG-IL2 (polyethylene glycosylated IL-2), roxithromycin, spiramycin, trimetrexate. Patients must have the following: - AIDS or Advanced ARC. - Patients eligible to enter this protocol must fall into one of the following three categories: - AZT treatment failure or AZT intolerance or AZT ineligibility or Rollover Patients Under 18 years of age must have the consent of a parent or guardian. Exclusion Criteria Patients with the following are excluded: - Any history of peripheral neuropathy due to any cause, even if peripheral neuropathy was not the reason for discontinuation of other anti-HIV therapy. - Any finding suggestive of peripheral neuropathy found at baseline neurological exam. If a patient has an isolated finding of an absent achilles reflex he may be entered if no signs or symptoms and no other findings are suggestive of peripheral neuropathy. - Concomitant treatment with excluded medications. Excluded medications include any other experimental drugs (including ddI), drugs with known nephrotoxic or hepatotoxic potential, and drugs likely to cause peripheral neuropathy. Any = or > Grade 3 laboratory or clinical abnormality or any severe abnormality not listed requires permission from the medical monitor to be entered into this study.. - Unwillingness or deemed unable to sign informed consent.
Total Enrollment:
Location and Contact Information:
Hoffmann - La Roche Inc
Nutley, New Jersey, 071101199
United States
Additional Information:
Study ID Numbers: 031D; N3663
Study Start Date:
Record last reviewed: August 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002256
Other Hiv Infections Studies:
1. A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination with Two Other Anti-HIV Drugs
2. Dehydroepiandrosterone Effects on HIV-1 Replication
3. Metabolism and Body Shape of Healthy Children and Children with Chronic Infections
4. ALVAC-HIV vCP1452 Alone and Combined with MN rgp120
5. An HIV Vaccine Preparedness Study
Related Studies:
Other HIV Infections Clinical Trials
Other New Jersey Clinical Trials
Other Nutley Clinical Trials
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients with AIDS or Advanced ARC who Cannot be Maintained on Zidovudine ( AZT ) Therapy.
|
|
|
|
|
|
|
|
